Stay updated with breaking news from Rev Oncol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Epcoritamab demonstrated clinically meaningful efficacy in challenging to treat, highly refractory LBCL patients, including patients previously treated with chimeric antigen receptor (CAR) T-cell
Company AnnouncementBased on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next stepsData from the clinical trial to be presented at a future medical meetingLarge B-cell lymphoma (LBCL) is a common form of non-Hodgkin’s lymphoma (NHL...
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities t
Company Announcement Based on the topline results from the EPCORE™ NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to...
Company Announcement Based on the topline results from the EPCORE NHL-1 clinical trial, Genmab and AbbVie will engage global regulatory authorities to discuss next steps Data from the clinical